AI Analysis | Feedback

Here are 1-3 brief analogies to describe Day One Biopharmaceuticals:

1. It's like a startup aiming to be the next Alexion Pharmaceuticals, but specifically targeting rare pediatric brain cancers.
2. Think of it as a very early-stage version of a company like Genentech, focused exclusively on developing breakthrough targeted therapies for specific genetic cancers.
3. Imagine Amgen in its very early days, solely focused on discovering a single, life-changing drug for children with a rare form of brain cancer.

AI Analysis | Feedback

```html

• DAY101: An oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor in Phase II clinical trials for pediatric low-grade glioma.
• Pimasertib: An oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.

```

AI Analysis | Feedback

Day One Biopharmaceuticals (DAWN) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for genetically defined cancers. Its lead product candidate, DAY101, is currently in Phase II clinical trials, and Pimasertib is also under development.

As a clinical-stage company with products in the development and clinical trial phases, Day One Biopharmaceuticals does not currently have approved products on the market generating commercial sales. Therefore, it does not have major customers in the traditional sense of selling its therapies to other companies (such as distributors, hospitals, or pharmacies) or directly to individuals. The company is primarily engaged in research and development and conducting clinical trials.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

The key risks to Day One Biopharmaceuticals (DAWN) are as follows:

1. Acquisition Completion Risk

The most significant and immediate risk for Day One Biopharmaceuticals and its shareholders is the possibility that its agreed-upon acquisition by Servier for $21.50 per share may not be completed. The transaction, expected to close in the second quarter of 2026, is subject to customary conditions, including regulatory clearances. If the acquisition fails to finalize due to regulatory hurdles, a failure to meet closing conditions, or other unforeseen events, Day One's stock price could experience a substantial decline. This would expose the company to the standalone operational risks inherent to a biopharmaceutical company that the acquisition currently mitigates.

2. Clinical Development and Regulatory Approval Risks

As a clinical-stage biopharmaceutical company, Day One Biopharmaceuticals faces inherent and substantial risks related to the successful development and regulatory approval of its product candidates, such as DAY101 (Ojemda) and Pimasertib. Clinical trials are complex, costly, and can fail at any stage due to lack of efficacy, unexpected adverse side effects, or other issues. The company must navigate rigorous regulatory processes to obtain marketing approvals, which are not guaranteed and can be subject to delays or denial. Negative outcomes in clinical trials or regulatory decisions could significantly impede the company's ability to bring its therapies to market.

3. Commercialization and Customer Concentration Risks

Even if Day One's product candidates, such as DAY101 (Ojemda), receive regulatory approval, there is no guarantee of successful commercialization or widespread market adoption, particularly given the competitive landscape in the oncology sector. Furthermore, Day One Biopharmaceuticals has a significant reliance on a limited number of large customers for its revenue. As of September 30, 2024, three customers accounted for all of the company's net product revenue, with a single customer representing 66.6%. This high concentration means that the loss of, or a significant reduction in demand from, any of these key customers could severely diminish net sales and negatively impact the company's operating results.

AI Analysis | Feedback

null

AI Analysis | Feedback

Day One Biopharmaceuticals' main product, DAY101 (tovorafenib, marketed as OJEMDA), targets pediatric low-grade glioma (pLGG).

Addressable Markets:

• DAY101 (OJEMDA/Tovorafenib) for Low-Grade Glioma (which includes pediatric low-grade glioma):
  • The global low-grade glioma market size was valued at approximately USD 935 million in 2024 and is projected to reach USD 1,341 million by 2032. Other estimates place the global market at USD 1.24 billion in 2024, with a projection to reach USD 1.87 billion by 2033. Another report estimated the market at USD 1.1 billion in 2025, growing to USD 1.8 billion by 2035.
  • The low-grade glioma market in the U.S. was estimated to be more than USD 550 million in 2023 and is expected to grow from 2024–2034.
• Pimasertib: null

AI Analysis | Feedback

Day One Biopharmaceuticals (DAWN) is poised for significant revenue growth over the next 2-3 years, driven primarily by the expanding commercialization of its lead product, OJEMDA, and strategic pipeline advancements.

Here are the key expected drivers of future revenue growth:

1. Increased Adoption and Duration of Therapy for OJEMDA in Relapsed/Refractory pLGG: OJEMDA (tovorafenib) received U.S. FDA approval in April 2024 for pediatric patients with relapsed or refractory low-grade glioma (pLGG). The company experienced strong demand, increasing prescriber adoption, and significant growth in prescription volumes throughout 2025. Day One Biopharmaceuticals reported $155.4 million in net product revenue for 2025, marking a 172% year-over-year increase, and has provided fiscal 2026 revenue guidance for OJEMDA between $225 million and $250 million, representing approximately 50% growth at the midpoint over 2025. The long median duration of therapy, trending at 19 months for commercial patients and a median time to next treatment of 42.6 months, is expected to further contribute to sustained revenue.
2. Potential Indication Expansion for OJEMDA to Front-line pLGG: Day One is actively pursuing the development of OJEMDA as a front-line therapy for newly diagnosed pLGG. The pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial is enrolling patients, with completion expected in the first half of 2026 and key data readouts anticipated. Successful completion and regulatory approval for this broader indication would significantly expand the addressable patient population and market opportunity for OJEMDA, leading to substantial revenue growth.
3. International Commercialization of OJEMDA through Ipsen Partnership: In July 2024, Day One Biopharmaceuticals entered into an exclusive licensing agreement with Ipsen to commercialize tovorafenib (OJEMDA) in territories outside the U.S. This partnership provides a mechanism for Day One to generate revenue from ex-U.S. sales through milestone payments and tiered double-digit royalties on net sales. Ipsen anticipates a mid-2026 EMA approval decision for OJEMDA in Europe, which would trigger additional payments and the commencement of royalties.
4. Advancement and Potential Commercialization of New Pipeline Assets (Emi-Le and DAY-301): Day One expanded its pipeline with the acquisition of Mersana Therapeutics in January 2026, adding Emi-Le, a B7-H4-directed ADC in Phase 1 for adenoid cystic carcinoma (ACC). Updated clinical data for Emi-Le is expected in mid-2026. Additionally, the company is advancing DAY-301, a PTK7-targeted ADC, which began dose escalation in late 2024 with initial clinical data anticipated in the second half of 2026. Successful development and eventual commercialization of these novel targeted therapies could open new revenue streams in high-value oncology indications beyond pLGG.

AI Analysis | Feedback

Share Repurchases

No information is available regarding share repurchase programs or activities by Day One Biopharmaceuticals (DAWN) over the last 3-5 years.

Share Issuance

• Day One Biopharmaceuticals completed its Initial Public Offering (IPO) on May 26, 2021, issuing 10,000,000 shares at $16.00 per share and raising gross proceeds of $160.0 million. The underwriters were also granted an option to purchase an additional 1,500,000 shares.
• The company closed an underwritten public offering on June 12, 2023, issuing 13,269,231 shares of common stock at $13.00 per share, generating gross proceeds of approximately $172.5 million.
• The number of outstanding shares increased by 10.70% in one year. [cite: 5 from prior search]

Inbound Investments

• Servier announced a definitive agreement on March 6, 2026, to acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the total equity at approximately $2.5 billion. This transaction is anticipated to close in the second quarter of 2026.

Outbound Investments

• In January 2026, Day One Biopharmaceuticals acquired Mersana Therapeutics to expand its pipeline, involving an upfront payment of $128.8 million.

Capital Expenditures

• Day One Biopharmaceuticals reported capital expenditures of approximately $320,000 in the last 12 months (likely fiscal year 2025). [cite: 5 from prior search]